Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.
By Shaji K. Kumar, J. Mikhael, F. Buadi, D. Dingli, A. Dispenzieri, R. Fonseca, M. Gertz, P. Greipp, S. Hayman, R. Kyle and 12 more. Mayo Clinic proceedings, 2009
655 citations recorded by the source corpus.
Subfields: Hematology, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/424cd4790a2003a5a4a4baad22acf18f761865bc
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Molecular Biology
In Oncology
Citations in the corpus
- Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management (2020, background): “(11;14), t(4;14), t(14;16), t(6;14), t(14;20), trisomies, and del(17p) (see risk-stratification below).(24) Conventional karyotyping to detect hypodiploidy and deletion 13 has value, but if FISH studies are done, addi-”
- Multiple myeloma: 2022 update on diagnosis, risk stratification, and management (2022, background): “Bone marrow studies at the time of initial diagnosis should include fluorescent in situ hybridization (FISH) probes designed to detect t(11;14), t(4;14), t(14;16), t(6;14), t (14;20), trisomies, and del(17p) (see risk stratification below).(26) Conventional karyotyping to detect hypodiploidy and del”